Published in Cancer Weekly, September 15th, 1997
The drug, a topoisomerase I inhibitor which has been designated "RFS 2000" by the company, is patented and is a semi-synthetic derivative of a naturally-occurring plant alkaloid with cancer-killing properties. It is extracted from the bark and leaves of the Camptotheca acuminata tree, which is native to China.
RFS 2000 currently is in Phase II human trials for pancreatic cancer, for which Orphan Drug Status already has been obtained from the U.S. Food...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.